DUBLIN--(BUSINESS WIRE)--The "Companion Diagnostic Markets - The Future of Diagnostics by Application, Technology and Funding with Customized Forecasting/Analysis, and Executive and Consultant Guides" report has been added to ResearchAndMarkets.com's offering.
Will Personalized Companion Diagnostics become the norm for diagnostics?
Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. Find out the latest outlook for this important market.
Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. Science is racing forward. And the cost of molecular diagnostics continues to fall.
"Companion Diagnostic Markets, the Future of Diagnostics" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of United States Medicare Fee Payment Schedules to help understand the New Nucleic Acid Test Pricing in detail. Forecast demand for new testing regimes or technologies.
Make research investment decisions. Specific growth and market size estimates for your area of interest is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.
The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.
Key Topics Covered:
1 Market Guides
1.1 Strategic Situation Analysis
1.2 Guide for Executives, Marketing, Sales and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
2 Introduction and Market Definition
2.1 What are Companion Diagnostics?
2.2 The Personalized Medicine Revolution
2.3 Market Definition
2.3.1 Revenue Market Size
2.4 Methodology
2.4.1 Methodology
2.4.2 Sources
2.4.3 Authors
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics
3 Market Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Instrumentation Supplier
3.1.4 Chemical/Reagent Supplier
3.1.5 Pathology Supplier
3.1.6 Independent Clinical Laboratory
3.1.7 Public National/regional Laboratory
3.1.8 Hospital Laboratory
3.1.9 Physicians Office Lab (POLS)
3.1.10 Audit Body
3.1.11 Certification Body
3.2 Personalized Medicine and Companion Diagnostics
3.2.1 Basics
3.2.2 Method
3.2.3 Disease risk assessment
3.2.4 Applications
3.2.5 Diagnosis and intervention
3.2.5.1 Companion Diagnostics
3.2.6 Drug development and usage
3.2.7 Respiratory proteomics
3.2.8 Cancer genomics
3.2.9 Population screening
3.2.10 Challenges
3.2.11 Regulatory oversight
3.2.12 Intellectual property rights
3.2.13 Reimbursement policies
3.2.14 Patient privacy and confidentiality
3.3 Chromosomes, Genes and Epigenetics
3.3.1 Chromosomes
3.3.2 Genes
3.3.3 Epigenetics
3.4 Cancer Genes
3.4.1 Germline vs Somatic
3.4.2 Changing Clinical Role
3.5 Structure of Industry Plays a Part
3.5.1 New Pharmaceutical Funding Market
3.5.2 Economies of Scale
3.5.2.1 Hospital vs. Central Lab
3.5.3 Physician Office Labs
3.5.4 Physicians and POCT
4 Market Trends
4.1 Factors Driving Growth
4.1.1 Level of Care
4.1.2 Immuno-oncology
4.1.3 Liability
4.1.4 The Aging World
4.2 Factors Limiting Growth
4.2.1 State of knowledge
4.2.2 Genetic Blizzard
4.2.3 Protocol Resistance
4.2.4 Regulation and coverage
4.3 Instrumentation, Automation and Diagnostic Trends
4.3.1 Traditional Automation and Centralization
4.3.2 The New Automation, Decentralization and Point Of Care
4.3.3 Instruments Key to Market Share
4.3.4 Bioinformatics Plays a Role
4.3.5 PCR Takes Command
4.3.6 Next Generation Sequencing Fuels a Revolution
4.3.7 NGS Impact on Pricing
4.3.8 Whole Genome Sequencing, A Brave New World
4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
4.3.10 Shifting Role of Diagnostics
5 Companion Diagnostics Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 JaxBio to Create Array-Based Cancer Tests
5.3 Agilent, Qiagen Win FDA Approvals Companion Diagnostics
5.4 Navignostics Using Single-Cell Spatial Proteomics
5.5 HMNC Brain Health to Develop Companion Diagnostics
5.6 Propath UK, Nucleai Partner on Spatial Proteomics
5.7 Becton Dickinson, Labcorp Collaborate for Flow Cytometry-Based Companion Diagnostics
5.8 Almac, AstraZeneca Strike CDx Development Pact
5.9 Avalon GloboCare, Lu Daopei Hematology Institute to Develop Cell Therapy CDx
5.10 Burning Rock Secures Lung Cancer NGS Test Approval in China
5.11 TenSixteen Bio Developing Drugs, Companion NGS Tests
5.12 Guardant Health Plans New Comprehensive Assay
5.13 Thermo Fisher, Oncocyte Ink Comarketing Deal for Cancer IVDs
5.14 Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test
5.15 Japanese Approves Thermo Fisher Scientific Oncomine Assay as CDx
5.16 Promega, Henlius to Develop Microsatellite Instability CDx for Cancer Drug
5.17 Natera Aims to Lead Market in Solid Tumor Adjuvant CDx
5.18 Oncocyte Details Expansions Plans
5.19 Agilent Acquires Resolution Biosciences
5.20 Qiagen, Inovio Expand CDx Partnership
5.21 AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance
5.22 NeoGenomics to Grow Through CDx Agreements, Acquisitions
5.23 Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction
5.24 Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
5.25 FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies
5.26 Promega to Develop MSI Assay as CDx
5.27 Guardant Health to Develop CDx for Janssen
5.28 Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx
5.29 FDA Approval for FoundationOneCDx
5.30 FDA finalizes CDx Guidance
5.31 QIAGEN Launches CDx Therascreen BRAF Test
6 Profiles of Key Players (Partial List)
- 10x Genomics, Inc
- Abbott Laboratories
- AccuraGen Inc
- Adaptive Biotechnologies
- Aethlon Medical
- Agilent/Dako
- Biocept, Inc
- Biodesix Inc
- BioFluidica
- BioGenex
- BioIVT
- Biolidics Ltd
- bioMerieux Diagnostics
- Bioneer Corporation
- Bio-Rad Laboratories, Inc
- CellMax Life
- Cepheid (Danaher)
- Charles River Laboratories
- Circulogene
- Dxcover
- Element Biosciences
- Enzo Biochem
- Epic Sciences
- Epigenomics AG
- Eurofins Scientific
- GILUPI Nanomedizin
- Guardant Health
- HansaBiomed
- HeiScreen
- Helomics
- HTG Molecular Diagnostics
- Invivoscribe
- Janssen Diagnostics
- Lunglife AI Inc
- MDNA Life SCIENCES, Inc
- MDx Health
- Menarini Silicon Biosystems
- Mesa Laboratories, Inc
- Natera
- NeoGenomics
- NGeneBio
- Novogene Bioinformatics Technology Co., Ltd
- Oncocyte
- OncoDNA
- Ortho Clinical Diagnostics
- Oxford Nanopore Technologies
- PamGene
- Panagene
- Perkin Elmer
- Qiagen
- Rarecells SAS
- RareCyte
- Roche Molecular Diagnostics
- Screencell
- Sema4 Holdings
- Sense Biodetection
- Siemens Healthineers
- simfo GmbH
- Stilla Technologies
- Sysmex Inostics
- Tempus Labs, Inc
- Thermo Fisher Scientific Inc
- Todos Medical
- Ultima Genomics
- Veracyte
- Volition
- Vortex Biosciences
- Vyant Bio
For more information about this report visit https://www.researchandmarkets.com/r/61suqi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
